How to Conduct a Travel Health Consultation: A Pharmacist's Guide

Pre-travel health consultations are one of the most clinically complex services a pharmacist can provide. Unlike a prescription renewal or a minor ailment assessment, a travel consultation requires the pharmacist to synthesize destination-specific epidemiological risk, the patient's individual health profile, current vaccine status, potential drug interactions, and a rapidly changing landscape of Health Canada travel health notices — all within a single encounter.

Done well, a pharmacist-led travel consultation is genuinely valuable to patients who might otherwise leave the country with no professional advice about preventable health risks. Done poorly — outdated vaccine guidance, missed contraindications, no documentation of clinical reasoning — it can cause harm and creates significant professional liability.

This guide covers the foundational structure of a travel health consultation, the clinical components every encounter must address, how to document your reasoning, and where pharmacist scope varies across Canada.

What Is a Pre-Travel Health Consultation?

A pre-travel health consultation is a clinical encounter in which a health care provider — in this case a pharmacist — assesses a traveller's destination-specific health risks and develops an individualized prevention plan. The goal is to reduce the likelihood of vaccine-preventable illness, vector-borne disease, travellers' diarrhea, altitude sickness, and other travel-related health risks through a combination of vaccination, medication, and patient education.

A travel consultation is not a checklist of vaccines. It is a risk-stratified clinical assessment. Two patients travelling to the same country may receive very different recommendations depending on their itinerary, duration of travel, activities planned, accommodation type, underlying medical conditions, current medications, pregnancy status, and immune status. The pharmacist's role is to integrate all of these variables into a coherent, individualized, evidence-based prevention plan.

The ideal timing for a travel consultation is at least 4 to 6 weeks before departure. Some vaccine series require multiple doses over several weeks. Some medications must be initiated before arrival in an endemic area. That said, a same-week consultation is still clinically valuable — not all preventive measures require lead time, and education about food safety, water precautions, insect bite prevention, and when to seek care abroad is relevant regardless of timing.

Scope and Authority Vary by Province

Before conducting travel consultations, pharmacists must understand the boundaries of their authority in their province. Travel health involves two distinct scopes: the authority to recommend and administer vaccines, and the authority to prescribe travel medications. These are not the same in every province, and neither should be assumed without confirming the current provincial regulatory framework.

In many provinces, pharmacists may administer vaccines that fall within their authorized immunization scope. However, the specific vaccines that pharmacists are authorized to administer vary by province and are updated as scope expands. Not all travel vaccines may be within scope in every province.

Yellow fever vaccine is a specific and important exception. Yellow fever vaccine must be administered only at a Health Canada–designated Yellow Fever Vaccination Centre (YFVC). Not all pharmacies are designated YFVCs. Pharmacists who administer yellow fever vaccine must practise within a designated centre, maintain the cold chain and documentation requirements, and follow the YFVC designation requirements for their province. If your pharmacy is not a designated YFVC, you must refer patients requiring yellow fever vaccination to an appropriate centre.

For travel medications — antimalarials, travellers' diarrhea standby therapy, altitude sickness medication, and similar products — pharmacist prescribing authority also varies by province. In some provinces, pharmacists with expanded prescribing authorization can prescribe certain travel medications directly. In others, a physician or nurse practitioner must prescribe, and the pharmacist's role is advisory and dispensing. In all cases, your provincial regulatory college's current standards are the governing documents. General national guidance — including this article — is not a substitute.

The Foundation: CATMAT and Key Guidelines

The Committee to Advise on Tropical Medicine and Travel (CATMAT) is the primary Canadian advisory body for travel health. Appointed by the Public Health Agency of Canada (PHAC), CATMAT develops and publishes evidence-based statements on malaria prevention, specific vaccine recommendations, travellers' diarrhea, altitude illness, vector-borne diseases, and other travel health topics. CATMAT statements are freely available through the PHAC website and represent the current Canadian evidence standard for travel health practice.

In addition to CATMAT, pharmacists conducting travel consultations should be familiar with:

• Health Canada Travel Health Notices: These notices provide current, destination-specific alerts for outbreaks, elevated disease activity, and other emerging risks. Critically, these notices change frequently — sometimes within weeks or even days. A destination's risk profile at the time of a patient's booking may be very different from its profile at departure. Current notices must be reviewed at the time of each consultation, not assumed to be the same as a previous visit.
• WHO International Travel and Health ("Green Book"): A comprehensive international reference covering destination-specific risks, disease distributions, and vaccine recommendations. Useful as a complement to CATMAT for destinations with limited Canadian-specific guidance.
• CDC Travelers' Health (Yellow Book): Published by the US Centers for Disease Control and Prevention. Widely used as a supplementary clinical reference, particularly for destination-specific disease risk maps and detailed antimalarial guidance. Note that some CDC recommendations differ from CATMAT — when discordant, Canadian pharmacists should generally follow CATMAT as the primary Canadian standard.
• NACI (National Advisory Committee on Immunization): Provides vaccine-specific guidance that informs travel immunization recommendations in Canada.

The practical implication: a travel consultation that relies on a textbook printed two years ago, or on a software database not updated to reflect current notices, may be dangerously out of date. Current guidance must be verified at the time of each individual consultation.

Essential Components of a Travel Consultation

Itinerary and Risk Assessment

Begin every consultation by establishing the precise itinerary. Country names alone are insufficient — risk can vary dramatically by region, altitude, urban vs. rural setting, season, and activity type within the same country. Document:

• All destination countries and specific regions or cities
• Departure date and total duration of travel
• Purpose of travel (tourism, visiting friends and relatives, business, volunteer or humanitarian work, adventure travel)
• Accommodation type (hotel, guesthouse, camping, staying with local family)
• Planned activities (urban only, rural or forested areas, freshwater exposure, high altitude, animal contact)
• Any planned medical care abroad (for patients with complex conditions)

Visiting Friends and Relatives (VFR) travel deserves particular attention. VFR travellers — typically immigrants or their descendants returning to their country of origin — are at significantly higher risk for many travel-related illnesses, including malaria, typhoid, and hepatitis A, because they often stay with family in local settings, eat local food and water, and may underestimate risk due to familiarity with the destination. They are also less likely to seek pre-travel consultation. Identifying VFR travel and communicating the risk explicitly is an important part of the consultation.

Routine and Travel Vaccines

Assess the patient's complete vaccination history. Routine Canadian immunizations — including MMR, varicella, hepatitis B, Tdap, and influenza — should be up to date before adding travel-specific vaccines. An incomplete routine schedule is a clinical gap that should be addressed at the travel consultation.

Travel-specific vaccines to consider depend entirely on the destination and patient profile. Common categories include (illustrative — confirm against current CATMAT guidance and destination-specific risk for each patient):

• Hepatitis A: Broadly recommended for most travel to developing regions with endemic risk. Confirm prior vaccination or serology.
• Typhoid: Considered for travel to areas with elevated food and water contamination risk, particularly in South Asia, sub-Saharan Africa, and parts of Latin America. Confirm strain-specific limitations of available vaccine formulations against current guidance.
• Yellow fever: Required for entry to some countries and recommended based on endemic risk in others. Requires designated YFVC — refer if your pharmacy is not designated.
• Hepatitis B: Relevant for travellers who may have medical procedures, sexual exposure, or prolonged stays in endemic regions.
• Rabies (pre-exposure prophylaxis): Consider for travellers with potential for animal contact in high-risk areas, especially where post-exposure biologics may be unavailable.
• Japanese encephalitis: Relevant for rural and agricultural travel in parts of Asia during transmission season.
• Meningococcal: Required for Hajj/Umrah pilgrims; consider for high-risk destinations in the meningitis belt of sub-Saharan Africa.

Document the patient's response to each vaccine consideration: accepted, declined, deferred, previously received (with date if known), or not indicated. This decision record is a core element of the clinical documentation.

Malaria Prophylaxis

Malaria assessment is one of the most clinically important components of any travel consultation for relevant destinations. The decision of whether chemoprophylaxis is needed — and if so, which agent is appropriate — requires integration of destination-specific malaria endemicity (by region and season), the patient's health profile, concurrent medications, and the duration and type of travel.

Refer to current CATMAT malaria prevention statements and destination-specific guidance for whether the destination carries malaria risk and whether chemoprophylaxis is indicated. Resistance patterns vary by region and influence the choice of antimalarial agent. The appropriate antimalarial per CATMAT guidance depends on the destination, regional resistance profiles, patient-specific contraindications, adherence likelihood, side effect profile, and cost — and must be selected on a per-patient basis, not as a default protocol.

Document the outcome of the malaria discussion clearly: whether prophylaxis was recommended, which agent class was selected per CATMAT and patient factors (without prescribing beyond your provincial scope), patient counselling provided on adherence and duration, and whether a prescriber communication was initiated where required.

Travellers' Diarrhea

Travellers' diarrhea is among the most common travel-related illnesses. The risk varies by destination — highest in parts of South and Southeast Asia, sub-Saharan Africa, and Latin America — and by travel behaviour. Counsel patients on food and water precautions as the primary prevention strategy, since no vaccine or medication provides complete protection.

Standby self-treatment — providing a patient with an antibiotic to carry and self-administer if they develop diarrhea meeting specified criteria — is commonly provided after travel consultation. In provinces where pharmacists have the prescribing authority to do so, this involves selecting an agent per CATMAT guidance considering destination-specific resistance patterns and patient factors. Where prescribing is outside your scope, communicate the recommendation to the prescriber. Document the counselling provided on when and how to use standby therapy, and when to seek care rather than self-treat.

Other Prevention Measures

A complete travel consultation addresses prevention beyond vaccines and medications:

• Insect bite prevention: Insect repellent (DEET or icaridin-based, appropriate concentration per CATMAT guidance for age), permethrin-treated clothing and bed nets for relevant destinations, and behavioural precautions
• Food and water safety: Specific guidance on what to avoid, water purification options, and bottled water reliability in specific destinations
• Sun and heat: Sunscreen, hydration, heat acclimatization for tropical destinations
• Altitude illness: For travel above approximately 2,500 m, counsel on acclimatization and discuss pharmacological prevention per CATMAT guidance for high-risk ascent profiles
• Blood clot prevention: For long-haul flights, particularly in patients with risk factors
• Sexual health and bloodborne disease: Relevant for certain travel purposes and destinations
• Medical kit and access to care: Travel health insurance, list of facilities at the destination, emergency contact protocols

Worked Examples: Brief Multi-Destination Snapshots

Documenting the Consultation

Travel consultation documentation must capture the full clinical encounter — not just the list of vaccines administered or prescriptions issued. A complete record protects you professionally, supports continuity of care, and demonstrates the clinical value of the pharmacist's contribution to the encounter.

A well-documented travel consultation includes:

• Date of consultation and date of planned departure
• Complete itinerary: All destinations, regions, duration, travel purpose, accommodation type, planned activities
• Patient health profile summary: Relevant medical conditions, current medications, allergies, immune status, pregnancy or breastfeeding status, age-specific considerations
• Vaccine history reviewed: What was confirmed, what was missing, what was updated
• Each vaccine considered with the outcome: Recommended and accepted, recommended and declined (with reason documented), not indicated (with reason), deferred pending prescriber consult, or referred to YFVC
• Malaria risk assessment and decision: Destination-specific risk assessed (with CATMAT reference), prophylaxis recommended or not indicated and why, agent class selected per CATMAT and patient factors if applicable, prescriber communication initiated if outside prescribing scope
• Travellers' diarrhea plan: Counselling provided, standby therapy decision and rationale
• Other prevention counselling documented specifically
• Patient education provided: Key points, materials given, patient's questions addressed
• Referrals made: To YFVC, prescriber, travel medicine clinic, or other provider
• Follow-up plan: Any second-dose visits scheduled, timeline for remaining vaccine series
• Pharmacist identification: Name, designation, license number

Clinical Reasoning and Risk Stratification

The distinguishing feature of a professional travel consultation — one that demonstrates pharmacist clinical expertise rather than a checklist exercise — is the quality of the documented clinical reasoning. A record that simply lists "Hepatitis A: recommended" tells the reader nothing about why it was recommended for this specific patient. A record that states "Hepatitis A vaccine recommended — travel to region with high endemic risk, no prior vaccination documented on provincial immunization record, 4 weeks to departure allows for one dose before travel" demonstrates active clinical reasoning.

Risk stratification — identifying which risks are highest for this specific patient based on their itinerary, activities, health status, and travel purpose — is the analytical foundation of the consultation. For each major risk category, document:

• Whether the risk was assessed as applicable to this patient's itinerary
• What specific factors elevated or reduced the risk (destination region, season, activities, patient health status)
• What prevention measure was recommended and why it was selected over alternatives
• Any patient-specific contraindications, interactions, or cautions that influenced the recommendation
• The patient's decision and the counselling provided

This level of documentation takes more time but is essential for clinical defensibility. Travel health is a high-complexity service — the documentation should reflect that complexity.

Common Travel Consultation Mistakes to Avoid

• Using outdated guidance: Travel health notices can change within days. A consultation that relies on software or print references not updated to reflect current outbreaks may provide inaccurate risk information. Always verify current notices at the time of each consultation.
• Assessing country-level risk instead of itinerary-level risk: "Going to [country]" is not a sufficient basis for risk assessment. Urban vs. rural, altitude, season, and specific regions within the same country can have radically different risk profiles.
• Missing VFR risk: VFR travellers are high-risk and frequently underconsult. Proactively address the misconception that familiarity with a destination reduces health risk.
• Not documenting declined recommendations: If a patient declines a recommended vaccine or medication, document the recommendation, the clinical rationale, the patient's decision, and the counselling provided. This is essential for professional protection.
• Referring for yellow fever vaccine without confirming YFVC status: Not all health care providers who give vaccines are designated YFVCs. Confirm that your referral is to a designated centre.
• Not accounting for drug interactions: Travel medications can interact with existing therapy in clinically significant ways. Malaria chemoprophylaxis agents, antimicrobials used for standby diarrhea therapy, and altitude medications all have interaction profiles that must be screened against the patient's current medications.
• Generic counselling documentation: "Patient educated on travel health" is not adequate. Document the specific points covered: which vaccines, what food and water precautions, how to use standby therapy, when to seek care.
• Prescribing beyond provincial scope: Confirm your prescribing authority for travel medications in your province before issuing prescriptions. When in doubt, communicate the recommendation to the patient's prescriber.

Tools That Streamline Travel Consultation Documentation

Travel consultation documentation is complex enough that structured tools offer significant clinical and efficiency value. A well-designed tool helps ensure that every destination's risk profile is systematically considered, that drug interactions are flagged, and that the final consultation record captures the full clinical encounter without relying on memory or manual reference lookups for each patient.

RPhNote's Travel Consultation module provides guided consultation workflows covering itinerary and risk assessment, vaccine staging, malaria and other chemoprophylaxis considerations, and patient education documentation. It incorporates destination profiles and references CATMAT, WHO, CDC, PHAC, and NACI guidelines, and generates a professional consultation document with pharmacy branding and pharmacist signature for the patient record.

As with any documentation support tool, all generated outputs require pharmacist review and approval before they become part of the patient record or are communicated to a patient. Travel health notices change frequently — verify that any tool-generated destination-specific guidance reflects current notices before relying on it. The pharmacist retains full professional responsibility for the accuracy, completeness, and clinical appropriateness of every recommendation, regardless of how the documentation was produced.

For an overview of how structured documentation supports broader pharmacy clinical practice, see the RPhNote documentation platform overview.

Frequently Asked Questions

Can pharmacists in Canada prescribe travel medications?

Pharmacist authority to prescribe travel medications varies by province. In some provinces, pharmacists with expanded prescribing authority can prescribe certain travel medications such as antimalarials or travellers' diarrhea standby therapy. In others, a physician or nurse practitioner must prescribe, and the pharmacist's role is advisory and dispensing. Pharmacists must confirm their specific prescribing authority with their provincial regulatory college before prescribing travel medications.

Can pharmacists administer yellow fever vaccine?

Yellow fever vaccine must be administered at a Health Canada–designated Yellow Fever Vaccination Centre (YFVC). Not all pharmacies are designated YFVCs. Pharmacists who administer yellow fever vaccine must practise within a designated centre and follow the YFVC requirements for their province. If your pharmacy is not a designated YFVC, refer patients requiring yellow fever vaccination to an appropriate centre.

What is CATMAT and why is it important for travel consultations?

CATMAT (Committee to Advise on Tropical Medicine and Travel) is the primary Canadian advisory body for travel health, operating under the Public Health Agency of Canada. It publishes evidence-based statements on malaria prevention, travel vaccines, travellers' diarrhea, altitude illness, and other travel health topics. CATMAT statements represent the current Canadian evidence standard for travel health recommendations and should be the primary reference for Canadian pharmacists — supplemented by current Health Canada travel health notices, WHO guidance, and CDC resources.

How far in advance should a patient see a pharmacist for a travel health consultation?

Ideally at least 4 to 6 weeks before departure. Some vaccine series require multiple doses over several weeks, and some medications should be started before arrival in an endemic area. That said, a late consultation is still valuable — partial protection is better than none, and education on food and water safety, insect bite prevention, and when to seek care abroad is relevant regardless of timing.

Do travel health recommendations differ by specific destination within a country?

Yes — significantly. Risk can vary by region, altitude, urban vs. rural setting, season, and type of travel within the same country. Malaria risk in particular is highly region-specific. Always assess the specific itinerary — not just the country name — and consult current destination-specific guidance from CATMAT and current Health Canada travel health notices at the time of each consultation.

Key Takeaways

• Pharmacist authority to prescribe travel medications and administer travel vaccines varies by province — confirm your scope before providing these services
• Yellow fever vaccine requires a Health Canada–designated YFVC — refer patients if your pharmacy is not designated
• CATMAT is the primary Canadian reference; always consult current Health Canada travel health notices at the time of each consultation, as these change frequently
• Assess itinerary-level risk, not just country-level risk — region, altitude, season, and activities can dramatically change the risk profile
• VFR travellers are high-risk and frequently underestimate their risk — address this directly during the consultation
• Document clinical reasoning for each recommendation, not just the recommendation itself — include why it applies to this specific patient
• Document declined recommendations as carefully as accepted ones — this is essential for professional protection
• All documentation tool outputs require pharmacist review before use — travel health notices must be verified current at the time of each consultation